Almost all work in this field will be based on collaborations of one type or another, during discovery, drug evaluation or, when successful, delivery of treatments
Needham, Mass. (PRWEB) March 18, 2010
Cambridge Healthtech Institute today announced its Inaugural Encouraging Development of Therapeutics for Neglected Diseases conference, to be held June 16-17, 2010 at the Sheraton Philadelphia City Center Hotel in Philadelphia, PA. This forum is designed to bring together many of the major stakeholders working on finding new therapeutics for diseases prevalent in developing countries, in order to examine and discuss strategies and best practices for solving the major challenges that prevent faster and more effective solutions.
There has been a significant increase in the level of activity and attention being paid to the development of therapeutics for neglected diseases over the past five years, but there are still considerable challenges in the road ahead. Diseases in the developed world receive a disproportional investment because of the commercial potential from large markets and the ability to pay for such treatment. Innovative approaches are being developed to stimulate interest and provide incentives for companies and other researchers to work on finding new therapeutics for diseases prevalent in developing countries.
"Almost all work in this field will be based on collaborations of one type or another, during discovery, drug evaluation or, when successful, delivery of treatments," says Phillips Kuhl, President of Cambridge Healthtech Institute. "The involvement of the Gates Foundation and others has increased the activity early in the pipeline, with lots of new discovery efforts. In some ways the bigger challenge is going to come as these projects mature, need to be evaluated at a larger scale and on the ground in the countries where they are needed. At those stages is when the limitations in healthcare infrastructure in those regions will really be felt."
The conference program will deal with topics such as strategies to improve collaboration with academics; ways to increase the contributions of companies in developing countries; leveraging opportunities in developed markets to support neglected disease products; development of vaccines, anti-virals and other anti-infectives; different models for funding and incentives for research and development; and more. The conference will feature speakers with first-hand experience in developing and commercializing therapeutics for diseases with reduced profitability. Speakers will talk from first-hand experience about what works and what doesn't as the program explores the most important new models, key issues, challenges and best practices of drug development for neglected diseases.
Featured speakers include a number of representatives from large pharma, covering both historical and more recent strategies being pursued in this area: Ken Gustavsen, Ph.D., M.B.A., Director, Global Product Donations, Office of Corporate Responsibility, Merck; Lydia Pan, Ph.D., Director, Science Policy, Pfizer; Drew Lewis, M.D., Head, Infectious Disease Development, Emerging Markets, Pfizer; Jacqueline B. Fine, Ph.D., Associate Director, Asset Management and Out-Licensing, External Scientific Affairs, Merck Research Laboratories; Nicholas Cammack, Ph.D., Senior Vice President & Head, Diseases for the Developing World, Medicines Development Campus, GlaxoSmithKline SL (Spain); Carlos Espinal, Ph.D., Director, Medical & Public Affairs Latin America, Public Policy and Government Relations US, Sanofi Pasteur; and Brigitta Tadmore, Ph.D., Vice President, Global Head, Diversity & Inclusion and Health Policy, Novartis Institute for BioMedical Research.
In addition, other featured speakers include representatives from the Gates Foundation, other not-for-profit and academics, as well as executives from biotechnology companies: Jan Gheuens, M.D., Ph.D., Senior Program Officer, Tuberculosis, Global Health Program, Infectious Diseases, Bill and Melinda Gates Foundation; Jeremy Carver, Ph.D., CEO & CSO, International Consortium on Anti-Virals; Beatrice Sequin, Ph.D., McLaughlin-Rotman Centre for Global Health, University of Toronto; Kate Marusina, Ph.D., Manager, Industry Alliances, CTSC, University of California, Davis; Michael Cynamon, M.D., Department of Medicine, SUNY Upstate Medical University; Denice Spero, Ph.D., Research Professor & Co-Director, Institute for Immunology and Informatics, University of Rhode Island; Rashmi H. Barbhaiya, Ph.D., CEO & Managing Director, Advinus Therapeutics Pvt Ltd, A Tata Enterprise; and John Garrett, Ph.D., Co-CEO, Glycosyn, Inc. The conference will close with a special guest presentation, via videotape, from Prof. Muhammad Yunus, winner of the 2006 Nobel Peace Prize, (Founder & Managing Director, Grameen Bank; Chairman, Grameen Healthcare Trust). "We are honored to be able to include a presentation by Prof. Yunus, a man of great vision and an inspiration to everyone who has a chance to hear him," noted Kuhl.
The Encouraging Development of Therapeutics for Neglected Diseases conference is immediately preceded by CHI's second annual Collaborative Innovation in Biomedicine conference being held June 14-16, 2010. Cambridge Healthtech Institute offers package pricing to attendees interested in participating in both conferences.
Please visit http://www.healthtech.com/ngl for more information.
About Cambridge Healthtech Institute (CHI)
Founded in 1992, Cambridge Healthtech Institute (CHI) (http://www.chicorporate.com ) is the industry leader offering the preeminent source of information to the leading researchers and business experts from top pharmaceutical, biotech, and academic organizations. Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, and Cambridge Healthtech Media Group.
Cambridge Healthtech Institute